Anticoagulant therapy with a selective thrombin inhibitor for acute cerebral infarction: Usefulness of coagulation markers for evaluation of efficacy

Journal of Thrombosis and Thrombolysis

Volumn 13, Issue 3, 2002, Pages 155-160

  Urabe, Takao ^a   Tanaka, Ryota ^a   Noda, Kazuyuki ^a   Mizuno, Yoshikuni ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Anticoagulant therapy; Argatroban; Cerebral infarction; Coagulation marker

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; BIOCHEMICAL MARKER; BLOOD CLOTTING FACTOR; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBIN INHIBITOR; THROMBOPLASTIN; ANTITHROMBIN; BIOLOGICAL MARKER; PIPECOLIC ACID DERIVATIVE; PLASMA PROTEIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; BRAIN ATHEROSCLEROSIS; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; EMBOLISM; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; PROTHROMBIN TIME; RECURRENT DISEASE; THROMBOPLASTIN TIME; TREATMENT OUTCOME; TREATMENT PLANNING; ACUTE DISEASE; BLEEDING; BLOOD; BLOOD CLOTTING TEST; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; THROMBOSIS;

ACUTE DISEASE; AGED; ANTICOAGULANTS; ANTITHROMBINS; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD PROTEINS; CEREBRAL INFARCTION; CEREBROVASCULAR ACCIDENT; EMBOLISM; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PIPECOLIC ACIDS; THROMBOSIS; TREATMENT OUTCOME;

EID: 0036624290     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020426906956     Document Type: Article

References (31)

1. Cerebral Embolism Task Force. Cardiogenic brain embolism. Arch Neurol 1986;43:71-84.
2. Nakamura K, Takano Y, Mori K. Thrombin-induced vasoconstriction in isolated cerebral arteries and the influence of synthetic thrombin inhibitor. Thromb Res 1985;40:715-720.
3. Imiya M, Matsuo T. In vitro and in vivo inhibition of platelet aggregation by argatroban (MD-805) in a patient with subacute cerebral thrombosis. Med Cons New Remed 1992;29:991-996.
4. Kawai Y, Yuki S, Sugimoto J, Tamao Y. Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J Pharmacol Exp Ther 1996;278:780-785.
5. Kobayashi S, Tazaki Y. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb Hemostasis 1997;23:531-534.
6. Uchiyama S, Yamasaki M, Hara Y, Iwata M. Alterations of platelet, coagulation, and fibrinolysis markers in patients with acute ischemic stroke. Semin Thromb Hemostasis 1997;23:535-541.
7. Matsuo T, Kario K, Matsuda S, Yamaguchi N, Kakishita E, on behalf of the Hyogo Argatroban Research Group. Effect of thrombin inhibition on patients with peripheral arterial obstructive disease: a multicenter clinical trial of argatroban. J Thromb Thrombolys 1995;2:131-136.
8. National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular disease III. Stroke 1990;21:637-676.
9. Moulin T, Cattin F, Créin-Leblond T, et al. Early CT sign in acute middle cerebral artery infarction: predictive value for subsequent infarct locations and outcome. Neurology 1996;47:366-375.
10. Adams RJ, Meador KJ, Sethi KD, Grotta JC, Thomson DS. Graded neurologic scale for use in acute hemispheric stroke treatment protocols. Stroke 1987;18:665-669.
11. Conway EM, Bauer KA, Barzegar S, Rosenberg RD. Suppression of hemostatic system activation by novel anticoagulants in the blood of patients with thrombotic diatheses. J Clin Invest 1987;80:1535-1544.
12. Boisclair MD, Ireland H, Lane DA. Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood Rev 1990;4:25-40.
13. Shah AB, Beamer N, Coull BM. Enhanced in vivo platelet activation in subtypes of ischemic stroke. Stroke 1985;16:643-647.
14. Feinberg WN, Bruck DC, Ring ME, Corrigan JJ Jr. Hemostatic markers in acute ischemic stroke. Stroke 1989;20:592-597.
15. Fisher M, Francis R. Altered coagulation in cerebral ischemia. Platelet, thrombin, and plasmin activity. Arch Neurol 1990;47:1075-1079.
16. Takano K, Yamaguchi T, Okada Y, Uchida K, Kisiel W, Kato H. Hypercoagulability in acute ischemic stroke: analysis of the extrinsic coagulation reactions in plasma by a highly sensitive automated method. Thromb Res 1990;58:481-491.
17. Tohgi H. Kawashima M. Tamura K, Suzuki H. Coagulation-fibrinolytic abnormalities in acute and chronic phase of cerebral thrombosis and embolism. Stroke 1990;21:1663-1667.
18. Takano K, Yamaguchi T, Kato H, Omae T. Activation of coagulation in acute cardioembolic stroke. Stroke 1991;22:12-16.
19. Yasaka M, Miyatake K, Mitani M, et al. Intracardiac mobile thrombus and D-dimer fragment of fibrin in patients with mitral stenosis. Br Heart J 1991;66:22-25.
20. Yamazaki M, Uchiyama S, Maruyama S. Alterations of hemostatic markers in various subtypes and phases of stroke. Blood Coagul Fibrinolysis 1993;4:707-712.
21. Marsh EF, Adams HP Jr, Biller J, et al. Use of antithrombotic drugs in the treatment of acute ischemic stroke. Neurology 1989;39:1631-1634.
22. Alberts MJ, Dawson DV, Massey EW. A follow-up survey of clinical practices for the use of heparin, warfarin, and aspirin. Neurology 1994;44:618-621.
23. Chamorro A, Vila N, Ascaso C, Blanc R. Heparin in acute stroke with atrial fibrillation. Clinical relevance of very early treatment. Arch Neurol 1999;56:1098-1102.
24. Kataoka S, Hirose G, Hori A, Shirakawa T, Saigan T. Activation of thrombosis and fibrinolysis brain infarction. J Neurol Sci 2000;181:82-88.
25. Yasaka M, Yamaguchi T, Miyashita T, Tsuchuya T. Regression of intracardiac thrombus after embolic stroke. Stroke 1990;21:1540-1544.
26. Minematsu K. Yamaguchi T. Management of hypertension in acute ischemic stroke. Jpn J Stroke 1997;19:441-444.
27. Shields RW Jr, Laureno R, Lachman T, Victor M. Anticoagulant-related hemorrhage in acute cerebral embolism. Stroke1984;15:426-437.
28. Pessin MS, Estol CJ, Lafranchise F, Caplan LR. Safety of anticoagulation after hemorrhagic infarction. Neurology 1993;43:1298-1303.
29. Okada Y, Yamaguchi T, Minematsu K, et al. Hemorrhagic transformation in cerebral embolism. Stroke 1989;20:598-603.
30. Matsuo H, Uematsu T, Umemura K, et al. A simple and reproducible cerebral thrombosis model in rats induced by a photochemical reaction and the effect of a tissue plasminogen activator in this model. J Pharmacol Toxicol Methods 1993;29:165-173.
31. Udeda T, Miyata S. Blood flow-improving effect of a thrombin inhibitor, argatroban, for progressive atherothrombotic cerebral embolism and prognosis of patients. Rinsho to Kenkyu 1998;75:233-241.